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1. Introduction
Recent developments in the field of regenerative medicine highlighted the emerging need
for cellular therapies. This novel approach is at the doorstep to its clinical application. Nev‐
ertheless, there is still a lack of consistent and unbiased data on the survival, distribution
and safety of implanted cells. The tight collaboration between pharmacology, chemistry, bi‐
ology and physics expanded the collection of methods for in vivo imaging and allowed for
real time assessment of functional read-outs, localization and viability of the implants. The
successful implementation of stem cell visualization will provide for improvements in many
healthcare fields. Of key importance is the identification of the most valuable method for
non-invasive monitoring of cells and affected tissue. In this chapter we will assess the ad‐
vantages and drawbacks of different imaging techniques, focusing specifically on cell thera‐
py and methods utilized for tissue engineering and regenerative medicine.
Organ transplantation still remains the gold standard for the treatment of terminally damaged
organs. This method brings along a collection of drawbacks like the shortage of available donor
organs and the high morbidity of immunosuppressive therapy. Regenerative medicine offers
an alternative for the replacement of organs and tissues overcoming pitfalls and proposing a
therapy with patient’s own cells. The discovery of the self-renewal and differentiation
capacities of stem cells accelerated the development of regenerative medicine and inspired
researchers and clinicians to search for novel treatment options for the improvement of the
quality of life of patients [1]. The tremendous success in medical sciences and biotechnology
allowed the development of many ideas, some of which are now being approved by clinical
trials. Nearly 26’000 studies utilizing cell therapy are currently ongoing [2] trying to establish
the safety and effectiveness of this new method for applications in neurology, cardiology or
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oncology. Autologous stem cell therapy is a novel promising approach with increasing impact
on regenerative medicine. Preliminary data of many preclinical studies on different human
disorders showed a beneficial effect of this treatment [3]. The usage of the patient’s own cells
to rebuild tissues and regain functionality after trauma is currently investigated, as it may have
a profound influence on many human diseases once its application is approved. Several
hurdles are yet to be overcome before the safety of this method is guaranteed. One possibility
to avoid the post mortem read-out of a study or the invasiveness of a biopsy is the use of in
vivo imaging. Succeeding in this would also significantly reduce the number of animal
experiments to be performed. The emerging need for “real time” visualization of cells and
tissue gives rise to many questions in the field of regenerative medicine. Many different cellular
therapies are on the door step into clinics and a method for non-invasive tracking of trans‐
planted cells and defining their fate, functionality and differentiation is of great importance.
Of high interest is also the visualization of their effect on the damaged tissue or organ.
In the past two decades many researchers concentrated on developing new modalities for
better visualization on the cellular and molecular level. As none of the available imaging
systems fulfils all needs, many efforts have been put into expanding the potential of the
available methods by testing the application of a variety of vectors, genes, proteins and cells
for precise read-outs. The visualization techniques relevant to clinical cell tracking include
positron emission tomography (PET), single-photon emission computed tomography (SPECT)
and magnetic resonance imaging (MRI) [4]. Hybridizations of computed tomography (CT) and
MRI with PET and SPECT allow simultaneous acquisition of anatomical information and
reveal new state-of-the-art modalities for successful molecular imaging (SPECT/CT, PET/CT,
PET/MRI) [5]. Generally, the utilization of radioactive tracers provides high sensitivity and
requires short image acquisition time. Nevertheless, the production of the radioactive isotopes
is very expensive and its application comes along with radiation exposure for the patient.
Therefore, MRI seems to be an attractive alternative devoid of harmful radiation. This modality
has spectacular image resolution and anatomical read-out capabilities [6]. However, it is more
time-consuming and lacks the high sensitivity of PET and SPECT [7] (see Table 1). There are
also a few optical imaging modalities using bioluminescence (BLI) or fluorescence (FI), which
have been widely utilized in small animal models [8]. These are cost-saving methods (using
fluorescent proteins or luciferase activity) which allow for very rapid result obtainment.
Nevertheless, their spatial resolution is low and decreases with depth, which is the main reason
why they are not applicable for life cell imaging in humans.
Many cells are potentially accessible by imaging and developments in this field already
support the diagnosis and therapy of several human diseases. However, a feasible technique
for non-invasive monitoring of the tissue engineering process is still missing. A variety of cells
was shown to be applicable for tissue and organ restoration, but yet little is known about the
safety, viability, functionality and migration of these cells in vivo and their direct or indirect
involvement in the healing process. Despite the abundance of new techniques for non-invasive
visualization of cells, their translation into the clinic is challenging. Hence, here we will discuss
the advantages and drawbacks of different imaging modalities applicable for humans and
their implementation in the diagnostics and monitoring of the treatment of various diseases
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located in the hot spot of current clinical trials. Moreover, we will consider potential strategies
for expansion of the available techniques, in particular for successful tissue engineering and
regenerative medicine.
Imaging
Modality
Spatial
Resolution
Temporal
Resolution
Sensitivity Safety Clinically
Applied
Cost
CT 50-200 µm (preclinical)
0.5-1 mm (clinical)
minutes not defined Ionizing
radiation
Yes $$
MRI 25-100 µm (preclinical)
~1 mm (clinical)
minutes-hours 10-3 – 10-5M
poor
No ionizing
radiation
Yes $$$
PET 1-2 mm (preclinical)
5-7mm (clinical)
seconds-minutes 10-11 – 10-12M
excellent
Ionizing
radiation
Yes $$$
SPECT 1-2 mm (preclinical)
8-10 mm (clinical)
minutes 10-10 – 10-11M
excellent
Ionizing
radiation
Yes $$
Table 1. Characterizations of clinical imaging modalities (adapted from [9]).
2. MR imaging
2.1. MRI basics
The  phenomenon  of  Magnetic  Resonance  Imaging  (MRI)  was  discovered  observing  the
reaction of certain nuclei, mostly  1H in the body, when placed in a strong magnetic field
(B0) [10]. Within a magnetic field, the sum of spins is a net magnetization aligned with the
applied field. The macroscopic magnetization is an effect of a slight excess of spins in “low
energy” state, in parallel to the B0 direction. The precession frequency of each atom with
magnetic  moment  is  directly  proportional  to  the  strength  of  the  magnetic  field.  After
applying a radiofrequency (RF) pulse which matches the precession frequency, some of the
“excess” atoms absorb energy and flip, thereby changing the direction of the net magneti‐
zation vector. The flip angle depends on the intensity, waveform and duration of the RF
pulse [11]. These atoms then re-emit the energy during transition to their original orienta‐
tion (relaxation) (Figure 1).
As already shown, MRI is based on a unique combination of radio waves and strong magnetic
fields, which allows the generation of cross-sectional images of the body in any plane.
Depending on the relaxation time after the RF pulse, one can distinguish between T1-and T2-
weighted images.
MRI is an imaging modality, which uses non-ionizing electromagnetic radiation and is thus
not harmful for patients. This is one of the strongest advantages of this technology over the
other methods described in this chapter.
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2.2. MRI applications
One of the biggest advantages of MRI is its high soft tissue contrast. This allows for very precise
images and simultaneous detection of functional, molecular and anatomical data. The tight
collaboration of science and medicine led to the clinical implementation of the MRI modality
for various diseases. Nevertheless, most of its potential remains at the pre-clinical state, as the
application safety of many methods is still under investigation. Cerebral perfusion imaging,
MR angiography flow imaging, cardiac MRI, functional MRI and MR spectroscopy are just a
few of the MRI sub-groups. However, up-to-date, MR is clinically mainly used for the imaging
of soft tissues.
A clinical trial study with patients suffering from acute myocardial infarction showed
successful implementation of MRI. Intracoronary infusions of bone marrow-derived stem cells
at different time points helped with cardio regeneration, which could be visualized by this
technique [12]. Another study is on its doorstep to clinics, gathering breast cancer patients for
breast restoration. The aim is to use MRI of autologous adipose-derived stem cells to visualize
the engraftment into the host tissue. The outcome of this study may have a great impact on
the utilization of MRI for cell tracking as a novel tool for breast tissue regeneration [13]. A
further example for the implementation of MRI for cell therapy studies was the evaluation in
a multiple sclerosis clinical trial. In this case, adult bone marrow derived stromal cells were
intravenously administered to the patients and MRI scans were performed to follow the
occurring changes. The main objective was to evaluate the effect of mesenchymal stem cell
transplantation on the number of Gadolinium (Gd)-positive lesions [14]. Another way of
addressing the safety and efficacy of using autologous mesenchymal stem cells as a possible
therapy for multiple sclerosis is being proposed by a group, using MR imaging for the
assessment of the therapeutic effect of the cell treatment [15]. All in all, MRI seems to be a
promising tool for monitoring therapy and diagnostic outcomes. Nevertheless, most of the
clinical studies using stem cell therapy in combination with MRI are focused on the visuali‐
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Figure 1. MRI scanner uses radiowaves and strong magnetic fields to obtain anatomical and functional body images. 1)
Atoms spin in random directions. 2) Applying a magnetic field makes atoms line up either in the direction of B0, or in
the opposite direction. The distribution is not exactly equal, as more atoms prefer to turn in “low energy” state, there‐
by creating a net magnetization parallel to B0. 3) Introducing a RF pulse makes half of the “excess” atoms change the
direction of their magnetization moment-to the “high energy” state. 4) Turning the RF off makes these atoms turn back
to their “low energy” position (relaxation), thereby emitting energy.
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zation of the regenerating soft tissue, rather than on the transplanted stem cells, their locali‐
zation, viability and safety.
Further efforts have been put into the development of strategies for bone and cartilage
regeneration. Recent studies are concentrating on developing a MRI-based method for
visualization of knee osteoarthritis by assessing the number and location of lesions, cartilage
thickness, and subchondral bone alteration at different time points [16]. Others went further
by using autologous adipose tissue derived mesenchymal stem cells (AD MSCs) as the most
hopeful candidate progenitor cell source for cartilage tissue engineering in patients with
degenerative arthritis. Promising results showed improved knee functions and reduced pain
without any adverse events. The cartilage regeneration process was captured by MRI at
different time points, showing decreased size of cartilage defect, while the volume of cartilage
increased over time in the high-dose patients (Figure 2) [17]. This depicts an excellent example
of the gradual morphologic regeneration process, visualized by means of MRI.
Figure 2. MRI evaluation of articular cartilage regeneration in the medial and femoral condyles after intra-articular in‐
jection of autologous AD MSCs. Sagittal and coronal MRIs before, 3, and 6 months after AD MSCs injection depicted
the beneficial effect of the high-dose stem cell therapy upon cartilage regeneration by visualizing increase in thickness,
and significantly decreased defect size. (Reprinted from [17], Copyright (2014), with permission from “John Wiley and
sons” and Kang Sup Yoon, M.D., Ph.D.)
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Besides its tremendous spatial resolution for visualization of soft tissues, MRI has proven
successful in the imaging of the spinal cord and column. There are several clinical studies
concentrating on the regeneration of this region using mesenchymal stem cell (MSC) trans‐
plants after injury. One group is trying to evaluate the change of MSC-treated spinal cord injury
using MRI. Scans will be performed at 3 and 6 months after transplantation in order to track
the effects of the possible cell treatment and the different ways of application (intravenous,
intrathecal, into the spinal cord) [18]. The outcome of this trial will allow suggesting the most
beneficial cell delivery method for further studies. Another project was concentrating on the
visualization of spinal cord lesions inducing limb paralysis. The proposed treatment strategy
included injections of bone marrow derived stem cells. Again, the preferred non-invasive
imaging method for localization of the injuries was MRI [19]. It seems that MRI is a suitable
imaging tool to assess spinal cord lesions and their repair by stem cells. One group addressed
the safety and efficacy of autologous MSC injections in patients with chronic spinal cord injury.
The outcome of this study revealed changes in MRI such as decreased cavity size and the
appearance of fiber-like low signal intensity streaks [20]. An increasing amount of research is
concentrating on the transplantation of stem cells as a therapeutic tool, but still, most of the
data derives from pre-clinical models. Nevertheless, promising studies in humans reveal new
possible solutions for many disorders.
The implementation of contrast agents for enhancement of MRI offers higher contrast and
resolution. Gadolinium (Gd) and superparamagnetic iron-oxide (SPIO) are most commonly
used for direct stem cell labeling in clinical and preclinical trials, with SPIO particles offering
the highest sensitivity amongst all MR contrast agents. Despite initial reports that SPIO
labeling of stem cells is safe and does not affect cell biology, recent studies indicate certain
metabolic and functional changes. Therefore, some essential issues need to be considered
before accepting such agents for clinical trials. A recent study [21] used Gd-or SPIO-labeled
mesenchymal stem cells, transduced with a luciferase vector to monitor their viability via BLI.
The outcome showed a distinction between viable and non-viable Gd cells, correlating with
the luciferase signal. However, dead SPIO-cells indicated a persistent signal void in vivo, with
simultaneous decrease of luciferase activity. This demonstrates that the absence or presence
of a contrast agent signal alone does not prove for cell viability. Often, dead cells are being
phagocytized by macrophages and the labeling persists in the new “host cells”. Although Gd-
labeling of stem cells seems feasible [22], its main disadvantages are the large amounts of Gd
chelates needed to produce a signal, the toxic effect of Gd if released from the complex (affects
kidneys) and the lower sensitivity compared to SPIO. These issues should be taken into
consideration, as they might lead to false quantification of the imaging data. Recently, a new
Gd-based contrast agent (Dotarem®) was approved by the FDA for Phase III clinical studies
for MRI in brain, spine and associated tissues in adult and pediatric patients to detect areas
with disruption of the blood-brain barrier and/or abnormal vascularity [23]. These clinical
studies showed superiority of the enhanced over the unenhanced images of the CNS lesions.
All in all, contrast agents improve the quality of the images, but their side effects have to be
taken into consideration.
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Safety and efficacy of autologous stem cell therapies remains a big issue and a non-invasive
visualization tool like MRI is facilitating the refinement of the procedures. Since MRI provides
more biological and functional data than CT-without radiation-the system provides a huge
advantage for pediatric patients as well as patients needing multiple scans. This makes it a
superior imaging modality in many clinical studies and encourages more patients to sign up
for the trials, as the risk for unwanted complications is decreased. However, MRI does not
come with excellent sensitivity and abundant molecular probes compared to other techniques,
following in this chapter.
3. PET imaging
3.1. PET basics
Radionuclide-based positron emission tomography (PET) is one of the most sensitive molec‐
ular imaging techniques. Contrary to MRI, this technique uses radiation. The agents used for
the visualization are labeled with a positron emitting radionuclide (11C, 13N, 15O, 18F etc.) which
decays by emitting a positively charged particle (β+). A positron is a particle with the same
mass as an electron, but with an opposite charge. Every positron-emitting radionuclide has its
own positron range (traveling distance), depending on the energy of its β+-particle. The higher
the energy, the longer the distance and, therefore, the larger the loss of spatial resolution. Once
most of its energy is lost, the positron eventually annihilates with an electron from the
surrounding tissue, whereby their mass is converted into electromagnetic energy in the form
of high-energy photons [24]. The PET Imaging technique is based on the coincidence detection
of two 511 keV photons emitted simultaneously in opposite directions (180o apart). They are
collected by a ring system of photon-sensitive detectors (scintillation crystals), surrounding
the object of interest (Figure 3). Although the exact location of a single annihilation is unknown,
the acquisition of a large number of coincidence events over many angles can provide enough
information to reconstruct an image of the spatial distribution of radioactivity as a function of
time [5].
The idea for the development of the PET technique was developed in the 1950s and was
introduced only a few decades later [25] as a clinical device for neurology and cardiology.
Later, the need of precise anatomic localization and metabolic readout led to the invention of
new imaging strategies. Combining two complementary modalities can add anatomical
and/or physiological information to molecular imaging studies using software fusion of data.
This technology is most successful for studies of organs and tissues that do not move with
time, e.g. the brain [26]. Another approach allowing for simultaneous and/or sequential
obtainment of data by a single device is the fusion of PET with CT or MRI. The immense value
of combining the benefits of two imaging modalities in one instrument in order to assess
molecular as well as morphologic information is of major interest nowadays. These devices
allow for more exact attribution of the radioactivity to a specific anatomic site within the
patient. Another great impact on the expansion of possible PET applications is the increasing
availability of PET radiopharmaceuticals. Many researchers are working towards the devel‐
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opment of novel radiotracers for diagnosis and/or therapy of various diseases. Combinations
of new technologies and radioligands have already been applied in diverse studies and thus
provided many insights for the further development of personalized medicine.
3.2. PET applications
Great improvements have been made towards the diagnosis and the therapy monitoring of
cancer, brain and heart diseases, as well as for a variety of malignancies and organ/tissue
restorations. [18F]fluorodeoxyglucose ([18F]FDG) is the most widely used PET radiopharma‐
ceutical. It is a metabolic tracer and the mechanism of uptake is based on phosphorylation to
[18F]FDG-6-phosphate, which is not further metabolized. [18F]FDG has a wide range of
applications in oncology, neurology, cardiology and inflammation imaging.
In the past few years many researchers concentrated on cell-based therapies for the restoration
of damaged myocardium showing the involvement of different cell types in this process such
as: skeletal myoblasts, embryonic stem cells, bone-marrow derived stem cells, cardiac resident
cells, mesenchymal stem cells, and circulating progenitor cells. [27]. The introduction of cells
into the damaged myocardium seems to be a promising technique and therefore several tools
for assessing the viability, localization and metabolism of the injected cells have been evaluated
[28]. The implanted cells should be suitably labeled for detection via imaging, in order to be
distinguishable from the surrounding cells and structures. This can be achieved by PET
imaging using [18F]FDG. It was already shown to be feasible for dynamic tracking of [18F]FDG-
labeled progenitor cells during intracoronary injection after acute myocardial infarction [29].
One of the main glucose uptake sites in the body are skeletal muscles. Using PET imaging of
this glucose derivate allows for longitudinal assessment of skeletal muscle regeneration and
degeneration [30]. This allows for easy visualization by [18F]FDG uptake in response to physical
exercise, thus making muscle cells a good diagnostic tool for therapy of muscle disorders [31].
Whether this technology is suitable for regenerative medicine purposes has to be further
evaluated.
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βFigure 3. PET scanner detects coincidence of two 511 keV photons emitted in opposite directions after annihilation of apositron (β+) with an electron (e-) in the surrounding media. The signals are captured by scintillation crystals and am‐
plified by photomultipliers. These events are then collected to construct images depicting the activity distribution.
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Another application of this tracer was shown in a clinical study using bone marrow cells for
autologous stem cell therapy after myocardial infarction. They included the PET modality in
their experimental design and investigated the myocardial flow ([13N]NH3) and perfusion/
metabolism mismatch ([18F]FDG) [32]. The usage of PET for tracking in vivo cell retention of
adipose tissue-derived stem cells for myocardial regeneration also showed promising results
[33]. It seems that these cells support the cardiomyocyte regeneration and angiogenesis in the
implanted area. The PET/CT modality appears to be a promising technique for effective cell-
tracking in vivo, which is vital for a more in-depth investigation into future clinical applications.
Another possibility for PET application is the utilization of reporter-gene systems (e.g. Herpes
Simplex Virus type 1 thymidine kinase (HSV1-tk)) [34]. The main advantage of this method is
that the obtained signal is specific only to viable cells, as they are able to express the reporters.
This allows not only for visualization of acute cell retention, but also for viability read-outs [7].
HSV1-tk is currently the most investigated enzyme reporter gene for long term in vivo
visualization of cells applied in the treatment of various cardiovascular diseases [35-37]. Recent
studies also investigated the use of reporter gene tracking via PET imaging to track viable stem
cells in large animal models [38-40]. These studies confirm the potential of this novel method
to allow for a better understanding of the cell faith after implantation. Using cell-based
therapies for tissue engineering with stem and/or progenitor cells for boosting regeneration
seems to offer great possibilities in regenerative medicine. Therefore, the development of novel
methods for non-invasive imaging of implants in vivo is of high priority.
PET/CT has also become an essential tool for assessing prognosis and establishing treatment
decisions in oncology. This system found broad application, mainly in defining different
stages/locations of metastatic cancer. In this case PET is used for visualizing the increased
metabolic activity of the tumor and the addition of CT provides anatomical information on its
exact location in the body [41]. This helped immensely in the management of a broad spectrum
of malignancies, their diagnosis, staging and therapy-response-assessment. The most com‐
monly used radiopharmaceutical in clinics [18F]FDG was shown to be essential to the treatment
of a great range of pathologies. This can significantly contribute to precise therapy response
assessment possibly influencing the therapeutic management and treatment planning [42].
Another study revealed a promising application of fluorine-18 labeled amino acid-based
radiotracers for small cell lung cancer detection via PET imaging [43]. Furthermore, a recently
developed categorization method for differentiation of osteosarcoma phenotypes by compar‐
ing SUV values of PET radioligands for glucose metabolism ([18F]FDG), hypoxia ([18F]FMISO)
and bone remodelling ([18F]fluoride) showed promising results. These findings can improve
the future evaluation of the treatment strategy depending on the specificity of the malignancy
[44]. These tracers can be applicable also for regenerative purposes, studying the healing
process of e.g. bones. A current clinical study for bone reconstruction of the skull is examining
the regeneration after introducing an implant using PET/CT via [18F]fluoride. Succeeding in
this would help out many patients with cranial defects and significantly improve their quality
of life [45].
Cardiology also gained immense benefits from the development of the hybrid imaging systems
(e.g. correction of attenuation and evaluation of coronary classifications), CT for coronary
Non-Invasive Imaging Modalities for Clinical Investigation in Regenerative Medicine
http://dx.doi.org/10.5772/59356
183
angiography, and acquisition of 3-D hybrid images for the definition of heart viability and
diagnosis of cardiac inflammations and infections [46]. Recent advances in stem cell therapy
show promising results for myocardium restoration, neovascularization and enhancement of
perfusion [47-50].
Research on the central nervous system (CNS) mainly emphasized on mapping different
aspects of neurotransmitter activity, e.g. dopaminergic, cholinergic, serotonergic and gluta‐
matergic systems as well as beta-amyloid visualization for Alzheimer’s disease (AD) [5, 51,
52]. PET Imaging has been applied widely to detect and quantify subtle abnormalities in CNS
diseases. Therefore, this technology is also immensely popular as a modeling tool in CNS drug
discovery and development. It is used for evaluation of drug deposition, as well as for studying
disease biomarkers to monitor drug effects on brain pathologies [24]. Another CNS utilization
of this modality was shown in a promising study regarding spinal cord injury [53]. The
combined efforts of stem cell and neuroscience researchers made it possible to visualize the
spinal cord regeneration process on the cellular and molecular level. In order to explore the
effect of in vivo PET on tracking dopamine receptor positive stem cells transplanted into the
spinal cord, [11C]Raclopride was injected intravenously, followed by a scan. The accumulation
of signal in the site of injury showed successful tracking and localization of the injected cells.
These results suggest that PET with a radiotracer is a useful technique for functional studies
in developing cell-based therapies [54]. Similar experimental setups allowed for more rapid
progression of many pre-clinical and clinical studies of various CNS pathologies (e.g.
[11C]Methionine PET/CT in patients with cancer; [18F]FLT in pediatric patients with CNS
tumors [55]).
After the successful introduction of the PET/CT system to the clinics, the integration of PET with
MRI was the next step. This new hybrid technique allows for simultaneous functional PET
imaging combined with soft tissue morphological MR images. The novel approach brings better
contrast among soft tissues as well as functional imaging capabilities, when compared to PET/
CT. Nevertheless, this technology is still not clinically mature at this point. Technically, the
implementation of PET/MR faces three major issues: 1. The photomultiplier-based PET scanners
do not work in the proximity of the magnetic field of the MR scanner; 2. Metallic objects (e.g.
surface coils used to get the best MR quality images) interfere with gamma rays from PET,
resulting in unwanted attenuation; 3. MR data cannot be used for attenuation correction, as CT
data, which is a limiting factor for the use of PET in therapy response monitoring [56].
As PET signal processing might disturb the high-frequency signals of MRI, and conventional
PET electronics fail in an even weak magnetic field, it soon became clear that new solutions
had to be found to circumvent the joint interferences. One possibility would be to leave just
the PET crystals in the MR field, whereas the PMTs are positioned outside and connected to
the crystals by optical fibres. Another approach to avoid the disturbance would be to place the
PET and MR scanners remote to each other, but still linked by a common bed, so that the patient
does not move between the two scans. Last, but not least, the PMTs could be replaced by solid
state electronics which are not disturbed by the MR field [57]. Hence, various approaches were
developed during the last fifteen years for application in small animal studies, where the usage
of more PET tracers is allowed and where use is not as legally restricted, as in human studies.
For a review, see Herzog, 2012 [57]. Improvements in pre-clinical study design enable smooth
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transfer of knowledge and molecular measurements between species thereby facilitating
clinical translation. Recently, PET/MRI for human imaging became available as well, towing
to support form the industry. Siemens Healthcare first designed prototypes of a BrainPET/MRI
device and the first reports of patients have been communicated [58, 59]. This opened new
possibilities in the field of molecular imaging and prepared the development of an integrated
whole-body PET/MRI scanner. A recent study compared the performance of whole-body PET/
MRI to PET/CT of breast cancer patients and claimed that PET/MRI is a feasible technique for
usage in clinics, forgoing gamma radiation for high quality imaging with short examination
time [60]. Another example for implementation of this new technique was shown in a sarcoma
patient, who underwent chemotherapy and autologous stem cell injection. MRI showed
lesions in the upper and lower leg, whereas PET revealed high [18F]FDG uptake only in one of
the lesions (Figure 4). This case illustrates the benefit of combining different imaging modalities
in order to get more precise outcomes, thereby improving the application fields of personalized
medicine. This methodology might also be useful for the investigation of regenerative
processes in damaged organs or tissues, for example after autologous stem cell therapy for
boosting the healing progression.
Figure 4. Simultaneous whole-body PET/MRI acquired with a molecular MR (mMR) scanner in a 13-year old boy with
a Ewing sarcoma known for six years. The patient underwent standard chemotherapy together with autologous stem
cell transplantation. After i.v. injection of [18F]FDG whole body PET-MRI was carried out. MR resulted in two suspi‐
cious lesions: One in the left upper leg muscle region, and one in the left lower leg. While the lesion in the left upper
leg muscles showed intense [18F]FDG uptake, the other one was PET-negative (arrows). Follow-up confirmed a Ewing
sarcoma relapse in the left upper leg muscle region. (Reprinted from [60], Copyright (2014), with permission from
“Elsevier” and Prof. Dr. med. O. Sabri)
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The clinical application of the PET/MRI technique has to be further established. Nevertheless,
if MRI can replace CT for anatomical screening, it adds value as well as decreases radiation
exposure, which would be of great benefit for the patients. However, the ongoing question of
choosing the best suitable visualization method remains unanswered, as there is still insuffi‐
cient knowledge about which PET/MRI applications are superior to the well-known PET/CT
for a variety of clinical cases.
4. SPECT imaging
4.1. SPECT basics
Unlike PET, single photon emission computer tomography (SPECT) uses radiopharmaceuti‐
cals labeled with gamma emitters instead of positron emitters. The concept of transmission
and emission tomography, later developed into SPECT, was first introduced in the late 1950s.
This period is associated with phenomenal growth of Nuclear Medicine, when some of the
most prominent gamma-radiation emitting radionuclides (131I and 99mTc) were produced [61].
While the primary use of 131I was dedicated to thyroid cancer treatment, its use was later
expanded for imaging of the thyroid gland itself, its function and the therapy of hyperthyr‐
oidism. The development of a generator system for 99mTc (1960s) was an important break‐
through and today it is the most utilized element in the field of Nuclear medicine. Other typical
gamma emitting radionuclides utilized in SPECT are 123I, 67Ga and 111In. The most common
SPECT systems consist of a gamma camera with rotating NaI(Tl) detector modules located
between the photomultipliers and collimators (Pb) (Figure 5), an on-line computer for
acquisition and processing of data and a display system [62]. Generally, a target-specific SPECT
radiopharmaceutical consists of two parts: a gamma-emitting radionuclide and a targeting
biomolecule (e.g. peptide, antibody fragment) [63]. Similar to PET, SPECT also enables 3-D
imaging and hybrid systems (SPECT/CT) are available as well.
4.2. SPECT applications
Various stem cells hold promise for the treatment of many human diseases. However, little is
known about the exact function, location and survival of the transplanted cells. The usage of
the SPECT imaging modality to answer these questions revealed promising results. Clinical
studies with SPECT indicated evidence for efficacious imaging of transplanted radiolabeled
cells in cardiac disease. Encouraging results were obtained from studies using [99mTc]hexam‐
ethylpropylenamineoxine (HMPAO)-labeled stem cells. Comparison of intracoronary (IC) and
transendocardial (TE) delivery of the cells to the heart showed more intense retention signal
18h after cell injection in the TE patients [64]. Another study could illustrate homing of bone
marrow mononuclear cells TE injection after acute myocardial infarction. Cell retention was
successfully visualized in the damaged heart tissue [65]. Similar results were obtained by a
group showing homing of bone marrow progenitor cells after intracoronary transfer using the
same radiotracer [66]. Controversially, further experiments investigating the homing of the
same cells after myocardial infarction indicated very heterogeneous uptake of the 99mTc-labeled
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cells, but for all patients there was lack of or decreased uptake of cells in walls with perfusion
defects. The perfusion imaging was performed with thallium (201Tl) [67]. Although the safety
of autologous stem cell transplantation to the heart after infarction has been shown, it is still
not known how many of these cells actually remain in the damaged site, or in near proximity
to it. To address their homing and apoptotic rate, autologous bone marrow cells were labeled
with [111In]oxine and injected via intracoronary route. SPECT imaging was performed 24h after
the transplantation and showed homogenous tracer accumulation in liver and spleen, while
uptake in the heart was focal. Up to 10% of the injected cells were retained in the myocardium
[68]. Similar results regarding cell retention were obtained by [18F]FDG labeling of the cells
and detection by PET [69]. Further insights in this field were obtained from a trial using 111In-
oxine-labelled pro-angiogenic cells after intracoronary injection in patients at different time
points after myocardial infarction. SPECT imaging was utilized to monitor the cell retention,
showing highest values in patients with recent onset of the disease, progressively decreasing
in patients treated in an intermediate phase or at chronic stage [70]. The substantial amount
of radioactivity in the myocardium suggests correct homing of these cells. Nevertheless, most
of the injected cells still remain locked in other locations. One possibility for cell homing
improvement might be by significantly reducing their entrapment in filter organs.
Further investigations were made to detect angiogenesis after myocardial infarction utilizing
SPECT. This was assessed using a novel radiolabelled peptide ([99mTc]NC100692, Maracicla‐
tide), which has high affinity to an angiogenesis-related integrin (αvβ3) [71] (Figure 6). The
successful implementation of this tracer led to a follow-up study, addressing the effect of bone
marrow stem cells transplantation on angiogenesis in chronic ischaemic heart failure patients
[72]. The patients underwent SPECT imaging using the same [99mTc]RGD imaging peptide.
This new imaging tracer was shown to be feasible in patients with heart failure. However, the
changes with stem cell therapy did not reach statistical significance.
 
 
α β
Figure 5. Underlying principle of SPECT: (1) A radioisotope decays by emitting gamma rays. (2) A rotating gamma-
sensitive detector with a collimator in front indicates the scintillation site where gamma rays are parallel to the collima‐
tor pinholes. (3) The collected data is then transferred to photomultipliers and finally to a computer for analysis.
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Despite the immense progress in the field of stem cell imaging research, the pre-labeling
approach for cell visualization remains challenging for now. Most of the stem cell clinical trials
tend to utilize techniques for following the regenerative process (e.g. tissue growth, vascula‐
rization and functional recovery), rather than direct tracking of the injected cells [73]. The use
of autologous stem cell therapy for heart regeneration is of high importance for cardiomyop‐
athy patients and is showing promising results. However, the therapeutic effect is by now
mostly measured by an enhancement of the heart regional and global contractility as a cell
treatment outcome [73]. One other factor, often taken into consideration when testing a new
approach for cardio-regeneration, is the heart perfusion efficacy. This could be measured by
i.v. injection of [99mTc]sestamibi at rest, followed by an induction of pharmacologic stress by
i.v. adenosine application. Successful SPECT imaging at rest and post stress suggested a trend
towards improvement in cell-treated patients [74]. These non-invasive approaches are able to
effectively show the outcome of the therapy. Still, they do not answer the questions regarding
proper homing, or viability of the injected cells.
Another possibility to assess the regeneration process is by using direct labeling of certain
proteins, known to be connected to basic organ functions. This method was performed to
estimate the liver self-regeneration after hepatectomy via 99mTc-labeled galactosyl-human-
serum-albumin. The liver uptake value could be calculated from SPECT/CT images of patients
at different time points after surgery [75]. An additional visualization possibility for the hepatic
function was shown by [99mTc]phytate colloid uptake by the liver. As colloid uptake by
Figure 6. Illustration of localized angiogenesis-tracer uptake (Maraciclatide:top) in a region of perfusion deficit (MIBI:
bottom). A: short axis slice; B: long axis slice. Figure was provided by courtesy of Prof. Brian Hutton.
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perfused Kupffer cells is proportional to perfused hepatocyte mass, this could be used for
direct quantification of perfused liver mass by quantitative SPECT in cirrhotic patients [76].
Although the liver is well-known for its self-regeneration capacity, stem cell therapy seems to
boost this capacity. Several studies addressed the therapeutic effect of autologous stem cells
for liver regeneration [77-79]. Nevertheless, none of them assessed the fate of these cells in
vivo. Recently, the proper homing of injected autologous mesenchymal stem cells in the liver
of patients with advanced cirrhosis could be illustrated, as these cells have previously been
shown to have beneficial effect. The cells were labeled with [111In]oxine before intravenous
infusion and could be detected by SPECT/CT up to 10 days after application. Shortly after
injection, accumulation of signal was observed in the lungs, and gradually shifted to the liver
and spleen during the following hours to days [80]. Using SPECT for evaluation of stem cell
homing seems a feasible technique. However, the safety, exact mechanism of action and timing
of cell delivery have to be further estimated. There is need for more essential information about
the long-term benefit of stem cell therapies. Critical for the future success of SPECT is the design
of new and specific tracers for the detection, localization, and staging of a disease and for
monitoring of the regeneration process. In the past few decades, there is an increase in the
awareness of the importance of this imaging modality, its significant impact on diagnosis and
management of various diseases and successful visualization of potential treatments.
5. Conclusions and future directions
There is no perfect imaging modality for non-invasive cell tracking in clinics. The research
findings of the last few decades on the arena of imaging have prompted an intense interest of
many investors, who facilitated the translation of these ideas into clinics. Nevertheless, to date
no state-of-the-art imaging tool is capable of delivering an all-in-one solution. Many factors
have to be considered before choosing the proper visualization modality, depending on the
question to be addressed. There is emerging need for versatile imaging methods capable of
monitoring the autologous stem cells in vivo. Although developments in the field of non-
invasive visualization add significant costs and have to overcome many regulatory roadblocks,
it is the only way of translating the research into clinical treatments and to support future
medicine by providing new tailored treatments to patients.
Despite the immense progress in the field of personalized medicine, there are still many black
boxes, on which non-invasive imaging is beginning to shed light. One can observe an increased
awareness of the importance of these imaging modalities and their significant impact on
diagnosis and management of human disorders are being recognized. Brilliant ideas and
developments in this field are catalyzing the design of new strategies every day, giving rise to
possible solutions. A summary of the characteristics of the “perfect clinical imaging modality”
for stem cell tracking is given in Table 2. Nevertheless, such an all-in-one technique is not
available yet, but the development of hybrid imaging devices for multimodal imaging was a
big step towards the ideal system.
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1. Safe, non-toxic and biocompatible
2. Single-cell detection at any anatomic location
3. Limitless depth of penetration
4. High spatial and temporal resolution, excellent molecular sensitivity
5. No genetic modifications of the stem cells
6. Insignificant/no dilution with cell division
7. Possible quantification of cell number and viability
8. Serial and long term monitoring in patients up to several months/years
9. Insignificant/no uptake of tracer by non-target cells
10.Multimodality-based approach
11.Low costs
Table 2. Requirements for the design of the “perfect clinical imaging modality” for stem cell tracking
The techniques of SPECT/CT, PET/CT and PET/MRI are the state-of-the-art modalities for
successful biomedical molecular imaging. Various diseases related to metabolism, apoptosis,
tumors, genetics, and stem cells have been identified by these systems [62]. The same ap‐
proaches are already being successfully transferred in numerous clinical studies using
autologous stem cells for organ and tissue restoration. Nevertheless, the selection of a given
visualization technique depends on its strengths and weaknesses with respect to the intended
use. All currently developed molecular imaging techniques for stem cell tracking have inherent
limitations. For imaging of delivery and short-term homing of the injected stem cells in
different organs, a direct labelling approach may be the answer (iron oxide or [18F]FDG), even
though any potential toxicity must be taken into account. MRI offers the highest spatial
resolution and near real-time image guidance for cell delivery, although with significantly
lower molecular sensitivity than other modalities, such as PET or SPECT. For long-term cell
monitoring, reporter gene imaging, using PET or SPECT, appears to be a better choice.
Ultimately, finding the most suitable system or combination of systems for proper diagnosis
and/or treatment remains the essence of health care and personalized medicine.
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